Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
RAPP Stock Forecast 2026-2027
$38.04
Current Price
$1.82B
Market Cap
Buy 11
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RAPP Price Targets
+110.3%
To High Target of $80.00
+35.4%
To Median Target of $51.50
+5.2%
To Low Target of $40.00
RAPP Price Momentum
+7.1%
1 Week Change
+11.3%
1 Month Change
+271.1%
1 Year Change
+25.4%
Year-to-Date Change
-10.0%
From 52W High of $42.27
+392.1%
From 52W Low of $7.73
๐ TOP ANALYST CALLS
Did RAPP Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Rapport is one of their latest high-conviction picks.
Latest RAPP Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, RAPP has a bullish consensus with a median price target of $51.50 (ranging from $40.00 to $80.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $38.04, the median forecast implies a 35.4% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason N. Butler at Citizens, projecting a 110.3% upside. Conversely, the most conservative target is provided by Douglas Tsao at HC Wainwright & Co., suggesting a 5.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RAPP Analyst Ratings
11
Buy
0
Hold
0
Sell
RAPP Price Target Range
Low
$40.00
Average
$51.50
High
$80.00
Current: $38.04
Latest RAPP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RAPP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2026 | BTIG | Kambiz Yazdi | Buy | Reiterates | $53.00 |
| Apr 22, 2026 | BTIG | Kambiz Yazdi | Buy | Reiterates | $53.00 |
| Mar 11, 2026 | BTIG | Kambiz Yazdi | Buy | Maintains | $53.00 |
| Mar 11, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $46.00 |
| Feb 2, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Initiates | $43.00 |
| Dec 9, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $40.00 |
| Dec 8, 2025 | BTIG | Kambiz Yazdi | Buy | Reiterates | $47.00 |
| Nov 19, 2025 | BTIG | Kambiz Yazdi | Buy | Initiates | $47.00 |
| Nov 7, 2025 | Citizens | Jason N. Butler | Market Outperform | Maintains | $80.00 |
| Sep 16, 2025 | Truist Securities | Joon Lee | Buy | Initiates | $44.00 |
| Sep 8, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $34.00 |
| Aug 6, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Initiates | $31.00 |
| Jul 8, 2025 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $28.00 |
| Apr 8, 2025 | JMP Securities | Jason Butler | Market Outperform | Initiates | $28.00 |
| Oct 18, 2024 | Jones Trading | Justin Walsh | Buy | Initiates | $42.00 |
| Jul 2, 2024 | Stifel | Paul Matteis | Buy | Initiates | $35.00 |
| Jul 2, 2024 | Jefferies | Andrew Tsai | Buy | Initiates | $35.00 |
| Jul 2, 2024 | TD Cowen | Joseph Thome | Buy | Initiates | $N/A |
Rapport Therapeutics Inc. (RAPP) Competitors
The following stocks are similar to Rapport based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rapport Therapeutics Inc. (RAPP) Financial Data
Rapport Therapeutics Inc. has a market capitalization of $1.82B with a P/E ratio of 21.2x. The company generates $20.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -121.1% and return on equity of -28.3%.
Valuation Metrics
Market Cap
$1.82B
Enterprise Value
$1.35B
P/E Ratio
21.2x
PEG Ratio
0.8x
Price/Sales
91.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-121.1%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+26.2%
Current Ratio
27.1x
Debt/Equity
2.3x
ROE
-28.3%
ROA
-19.1%
๐ก SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Rapport Therapeutics Inc. (RAPP) Business Model
About Rapport Therapeutics Inc.
What They Do
Develops precision medicines for neurological disorders.
Business Model
Rapport Therapeutics operates as a clinical-stage biopharmaceutical company, generating revenue through the development and eventual commercialization of targeted small molecule therapeutics for central nervous system disorders. By focusing on receptor-associated proteins, the company aims to deliver more effective treatments with fewer side effects compared to traditional therapies.
Additional Information
Founded in 2022 through collaboration with Third Rock Ventures and Johnson & Johnson Innovation, Rapport is strategically located in Boston and San Diego, enhancing its access to leading biotech resources and talent. Its lead program, RAP-219, targets TARPฮณ8, which is linked to established epilepsy treatments, indicating a strong potential for market impact.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
84
CEO
Mr. Abraham N. Ceesay M.B.A.
Country
United States
IPO Year
N/A
Website
www.rapportrx.comRapport Therapeutics Inc. (RAPP) Latest News & Analysis
Latest News
Quick Summary
Rapport Therapeutics reported a 90% median seizure reduction for RAP-219 in focal onset seizures. Phase 2 trial results for bipolar mania are now expected Q4 2026. The company ended Q1 2026 with $476.8M in cash.
Why It Matters
RAP-219's strong Phase 2a results and upcoming Phase 3 trials enhance its potential market value. Strategic collaborations and solid cash reserves support continued development, signaling growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapport Therapeutics, Inc. (RAPP) reported a quarterly loss of $0.42 per share, better than the estimated loss of $0.56 and an improvement from a loss of $0.68 per share a year earlier.
Why It Matters
Rapport Therapeutics' smaller-than-expected quarterly loss indicates improving financial performance, potentially boosting investor confidence and positive market sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Crossject has released its 2025 annual financial report, available to the public and filed with the Autoritรฉ des Marchรฉs Financiers. The report can be accessed on the company's website.
Why It Matters
Crossject's 2025 financial report release indicates transparency and regulatory compliance, influencing investor confidence and potential stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AdVini has released its 2025 Annual Financial Report, now available to the public and filed with the Autoritรฉ des Marchรฉs Financiers. It can be accessed on their website.
Why It Matters
AdVini's annual financial report provides insights into its performance and strategies, influencing investor decisions and market perception of the company's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapport Therapeutics reported a 90% median reduction in clinical seizures during weeks 9-12 and 59% in weeks 13-16 of its Phase 2a trial for RAP-219. The drug has a half-life of 22 days and was well tolerated.
Why It Matters
RAP-219's significant efficacy in reducing seizures and its favorable half-life could enhance Rapport Therapeutics' market position, driving potential stock value increases and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Crรฉdit Mutuel Home Loan SFH has made its 2025 annual financial report available to the public on its website and the AMF site. Investors can contact Sandrine Cao Dac Viola for inquiries.
Why It Matters
The availability of Crรฉdit Mutuel Home Loan SFH's annual financial report allows investors to assess the company's performance, financial health, and future outlook, influencing investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RAPP Stock
What is Rapport Therapeutics Inc.'s (RAPP) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Rapport Therapeutics Inc. (RAPP) has a median price target of $51.50. The highest price target is $80.00 and the lowest is $40.00.
Is RAPP stock a good investment in 2026?
According to current analyst ratings, RAPP has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $38.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RAPP stock?
Wall Street analysts predict RAPP stock could reach $51.50 in the next 12 months. This represents a 35.4% increase from the current price of $38.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rapport Therapeutics Inc.'s business model?
Rapport Therapeutics operates as a clinical-stage biopharmaceutical company, generating revenue through the development and eventual commercialization of targeted small molecule therapeutics for central nervous system disorders. By focusing on receptor-associated proteins, the company aims to deliver more effective treatments with fewer side effects compared to traditional therapies.
What is the highest forecasted price for RAPP Rapport Therapeutics Inc.?
The highest price target for RAPP is $80.00 from Jason N. Butler at Citizens, which represents a 110.3% increase from the current price of $38.04.
What is the lowest forecasted price for RAPP Rapport Therapeutics Inc.?
The lowest price target for RAPP is $40.00 from Douglas Tsao at HC Wainwright & Co., which represents a 5.2% increase from the current price of $38.04.
What is the overall RAPP consensus from analysts for Rapport Therapeutics Inc.?
The overall analyst consensus for RAPP is bullish. Out of 10 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $51.50.
How accurate are RAPP stock price projections?
Stock price projections, including those for Rapport Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 3:45 AM UTC